Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate whether recombinant IL-21 used in combination with
rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).